Cancer Pharmacogenomics Development, Science, Translation

More documents

Recommendations

Info

Gemcitabine “Pathway” Gemcitabine SLC28A1,A2 and A3 SLC29A1 and A2 Deamination P CDA NDPs Gemcitabine RRM1 RRM2 Gemcitabine UMP-CMPK P P Gemcitabine RRM2B dNDPs dNTPs P P P P Gemcitabine P P dNTPs P Nucleus
Gemcitabine-AraC IC50 – Expression Association IC50 Gemcitabine IC50 AraC Reprinted with permission from Li et al. <strong>Cancer</strong> Res. 2008; 68:7050-7058.
Page 1 and 2: Cancer Pharmacogenomics Development
Page 3 and 4: Pharmacogenetics-Pharmacogenomics C
Page 5 and 6: Pharmacogenetics-Pharmacogenomics S
Page 7 and 8: Pharmacogenetics-Pharmacogenomics F
Page 9 and 10: • Low TPMT TPMT Genetic Polymorph
Page 11 and 12: Pharmacogenetics-Pharmacogenomics F
Page 13 and 14: CYP2D6 Pharmacogenetics Number of S
Page 15 and 16: Tamoxifen Pharmacogenetics No Tamox
Page 17 and 18: Cancer Pharmacogenomics • Introdu
Page 19: Cytidine Analogues Ara-C N NH 2 Gem
Page 23 and 24: The Therapeutic Revolution Goodman
Page 25 and 26: FKBP5 Functional Characterizatoin C
Page 27 and 28: Pharmacogenomics Genomic Era Develo
Page 29 and 30: Cancer Pharmacogenomics Challenges
Page 32: Mayo Pharmacogenomics Laboratories

Cancer Pharmacogenomics Development, Science, Translation

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?